Financials data is unavailable for this security.
View more
Year on year Shanghai Serum Bio-Technology Co Ltd had net income fall -39.54% from 64.14m to 38.77m despite a 9.14% increase in revenues from 174.22m to 190.14m. An increase in the cost of goods sold as a percentage of sales from 19.23% to 26.21% was a component in the falling net income despite rising revenues.
| Gross margin | 76.60% |
|---|---|
| Net profit margin | 25.81% |
| Operating margin | 31.11% |
| Return on assets | 4.48% |
|---|---|
| Return on equity | 4.62% |
| Return on investment | 4.56% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Serum Bio-Technology Co Ltd fell by 364.81m. However, the company earned 32.82m from its operations for a Cash Flow Margin of 17.26%. In addition the company used 315.94m on investing activities and also paid 81.84m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 10.30 |
|---|---|
| Tangible book value per share | 10.08 |
More ▼
Balance sheet in CNYView more
| Current ratio | 44.41 |
|---|---|
| Quick ratio | 42.72 |
| Total debt/total equity | 0.004 |
|---|---|
| Total debt/total capital | 0.004 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -73.33% and -39.54%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 42.50% |
| EPS growth(5 years) | -1.62 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -2.37 |
More ▼
